



EUROPEAN  
HEMATOLOGY  
ASSOCIATION



Ferrata Storti  
Foundation

# Ferroportin disease: pathogenesis, diagnosis and treatment

Antonello Pietrangelo

Center for Hemochromatosis, Department of Internal Medicine II, University of Modena and Reggio Emilia Policlinico, Modena, Italy

**Haematologica** 2017  
Volume 102(12):1972-1984

## ABSTRACT

**F**erroportin Disease (FD) is an autosomal dominant hereditary iron loading disorder associated with heterozygote mutations of the ferroportin-1 (*FPN1*) gene. It represents one of the commonest causes of genetic hyperferritinemia, regardless of ethnicity. *FPN1* transfers iron from the intestine, macrophages and placenta into the bloodstream. In FD, loss-of-function mutations of *FPN1* limit but do not impair iron export in enterocytes, but they do severely affect iron transfer in macrophages. This leads to progressive and preferential iron trapping in tissue macrophages, reduced iron release to serum transferrin (i.e. inappropriately low transferrin saturation) and a tendency towards anemia at menarche or after intense bloodletting. The hallmark of FD is marked iron accumulation in hepatic Kupffer cells. Numerous FD-associated mutations have been reported worldwide, with a few occurring in different populations and some more commonly reported (e.g. Val192del, A77D, and G80S). *FPN1* polymorphisms also represent the gene variants most commonly responsible for hyperferritinemia in Africans. Differential diagnosis includes mainly hereditary hemochromatosis, the syndrome commonly due to either *HFE* or *TFR2*, *HJV*, *HAMP*, and, in rare instances, *FPN1* itself. Here, unlike FD, hyperferritinemia associates with high transferrin saturation, iron-spared macrophages, and progressive parenchymal cell iron load. Abdominal magnetic resonance imaging (MRI), the key non-invasive diagnostic tool for the diagnosis of FD, shows the characteristic iron loading SSL triad (spleen, spine and liver). A non-aggressive phlebotomy regimen is recommended, with careful monitoring of transferrin saturation and hemoglobin due to the risk of anemia. Family screening is mandatory since siblings and offspring have a 50% chance of carrying the pathogenic mutation.

## Correspondence:

antonello.pietrangelo@unimore.it

Received: July 10, 2017.

Accepted: September 25, 2017.

Pre-published: November 3, 2017.

doi:10.3324/haematol.2017.170720

Check the online version for the most updated information on this article, online supplements, and information on authorship & disclosures: [www.haematologica.org/content/102/12/1972](http://www.haematologica.org/content/102/12/1972)

©2017 Ferrata Storti Foundation

Material published in *Haematologica* is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions:

<https://creativecommons.org/licenses/by-nc/4.0/legalcode>.

Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions:

<https://creativecommons.org/licenses/by-nc/4.0/legalcode>,

sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher.



## Introduction

The name Ferroportin Disease (FD) refers to a clinical entity that differs from all other known forms of hereditary iron overload, including hemochromatosis (HC) [synonymous for hereditary hemochromatosis (HH)], i.e. the syndrome due to either *HFE* or non-*HFE* hemochromatosis gene mutations.<sup>1</sup> In humans, a number of genetic disorders associate with systemic iron overload (Table 1) while others are caused by iron misdistribution and are associated with the regional accumulation of iron in subcellular compartments (e.g. mitochondria in Friedreich ataxia) or certain cell types and organs (e.g. basal ganglia in neuroferritinopathy) (Table 1). In strict terms, the latter disorders may not all qualify as true iron-overload states, as the total body iron content may not be increased. FD, which today accounts for one of the commonest forms of hereditary iron overload disorder besides *HFE*-hemochromatosis, is characterized by a unique pathogenic basis and clinical presentation and, unlike HC, has been reported worldwide, regardless of ethnicity.

Ferroportin Disease (phenotype MIM number 606069, gene/Locus; MIM number 604653; <https://www.omim.org/entry/606069?search=ferroportin%20dis>

ease&highlight=ferroportin%20disease) is due to pathogenic (usually missense) mutations of the ferroportin1 gene (*FPN1*; *SLC40A1*) which encodes the only iron exporter so far identified in mammals;<sup>2,4</sup> lack-of-function mutations impair the iron-export capability of FPN1, particularly in cells with high iron turnover, such as tissue macrophages. Unlike the mutations causing FD, other rare mutations of FPN1 (such as N144H, C326Y, C326S and C326F),<sup>5,8</sup> do not impair protein expression at the cell membrane or its iron export capability, but make FPN1 resistant to the inhibitory effect of hepcidin, the physiological FPN1 inhibitor (see below under Pathogenesis). This causes unchecked iron export activity of FPN1; the resulting clinical disorder is different from FD and indistinguishable from other forms of hereditary HC (Tables 1 and 2).

### Definition and classification

The OMIM database classifies the two forms of hereditary iron overload due to FPN1 mutations within the same taxonomic category as “hemochromatosis type 4” (<https://www.omim.org/entry/606069?search=ferroportin%20disease&highlight=ferroportin%20disease>). Similar terminology has then been adopted by Orphanet with the inclusion of two subcategories: hemochromatosis type 4A (referring to classic FD due to lack-of-function FPN1 mutations) and hemochromatosis type 4B (referring to FD due to gain-of-function FPN1 mutations) ([http://www.orphanet.net/consort/cgibin/OC\\_Exp.php?Lng=EN&Expert=139491](http://www.orphanet.net/consort/cgibin/OC_Exp.php?Lng=EN&Expert=139491)). These classifications have been incorporated into recent publications, with some variants.<sup>9,10</sup> Disease naming and classification (taxonomy) can vary depending on different criteria, such as pathogenic genes, mechanisms, clinical manifestations, etc. Ideally, disease taxonomy (and names) should also help clinicians to recognize, diagnose, and cure diseases. In this context, the taxonomy adopted by OMIM and Orphanet, by embracing two pathogenetically and clinically different disorders caused by mutations in the same gene under the term “hemochromatosis”, may fail to reach those objectives. Over the past decades, the term hemochromatosis has been inconsistently used in the literature and in clinical practice to imprecisely refer to: i) any form of body iron overload; ii) tissue iron overload causing organ damage and disease; iii) genetically determined iron overload; and, recently, iv) HFE-related iron

overload.<sup>11</sup> Recent discoveries in the field have shown that, regardless of the underlying genetic defect, a number of hereditary iron loading disorders (i.e. those due to loss-of-function mutations of HFE, TFR2, HJV, HAMP and gain-of-function mutations of FPN1) belong to the same syndromic entity as they share the pathogenic basis (lack of hepcidin function-activity), biochemical expressivity (high transferrin saturation and high serum ferritin), liver pathology features (iron accumulation in parenchymal cells with iron-spared Kupffer cells until late stage), damage and disease of distinct target organs (liver, heart, endocrine glands, joints), and the therapeutic approach with optimal response to phlebotomy.<sup>11</sup> As discussed in the following sections, each individual feature reported above is different in classic FD.<sup>1</sup> Therefore, using the term “hemochromatosis” for the classic FD or the term “Ferroportin Disease” for FPN1-associated HC, is misleading, particularly for clinicians, since clinical suspicion, diagnostic strategy and management differ profoundly. Based on these considerations, and on our present understanding of the pathogenesis and clinical manifestations of these disorders, it is proposed that the disorder due to lack-of-function mutations of FPN1 is termed “Ferroportin Disease”, as originally described,<sup>1</sup> and the disorder due to gain-of-function FPN1 mutations is termed “FPN-1 associated hemochromatosis” (Table 1). Instead, in analogy with other protein-related classifications (e.g. ferritinopathies; hemoglobinopathies), both disorders due to lack- and gain-of-function mutations of FPN1 may well be included in a broader taxonomic category named “ferroportinopathies”.

### Historical aspects

In 1996, the HFE hemochromatosis gene, whose C282Y homozygote mutation is responsible for most cases of HH in Caucasians, was identified.<sup>12</sup> Soon after, it became apparent that not all hereditary iron overload disorders could be explained by HFE mutations, particularly in Southern Europe, where an active search for other genes linked to genetic iron overload flourished. From 2000 to 2004, all known non-HFE genes associated so far with HC, namely transferrin receptor 2 (*TFR2*),<sup>13</sup> *FPN1*,<sup>5</sup> hepcidin (*HAMP*),<sup>14</sup> and hemojuvelin (*HJV*)<sup>15</sup> were identified.

A few years earlier, in 1999, a distinct and somehow unusual phenotype had been reported in a large family with hereditary iron overload from Italy. Selective iron

**Table 1. Human hereditary disorders associated with iron overload and iron mis-distribution.**

Iron overload		Iron mis-distribution	
Disorder/cause	Pattern of iron accumulation	Disorder/cause	Pattern of iron accumulation
Hereditary hemochromatosis (HFE-TfR2-, HJV-, HAMP-, FPN1-associated)	Systemic (iron accumulation in parenchymal cells)	X-linked sideroblastic anemias	Systemic (mitochondria)
Ferroportin Disease	Systemic (preferential iron accumulation in macrophages)	Friedreich ataxia	Systemic (mitochondria)
Aceruloplasminemia	Systemic	Neuroferritinopathy	Regional (brain)
Atransferrinemia	Systemic		
DMT-1 deficiency	Regional (mainly liver)		
H-ferritin-related iron overload	Systemic		
Hereditary iron-loading anemias with inefficient erythropoiesis	Systemic (early iron accumulation in hepatocytes due to increased iron absorption)		

loading of liver macrophages, hyperferritinemia co-existing with normal-low transferrin saturation, and tendency to anemia after intense phlebotomy were the hallmarks of the disorder.<sup>16</sup> In 2001, all affected family members were reported to be heterozygous for a c. 230 C→A substitution resulting in the replacement of alanine 77 with aspartate in FPN1.<sup>17</sup> This entity was subsequently named FD.<sup>1</sup>

On the other hand, FPN1-related HC, due to a gain-of-function mutation of FPN1 (p.N144H), was first reported by Njajou *et al.* in 2001.<sup>5</sup> Yet, it is worth mentioning that the first clinical description of an “autosomal dominant” form of classic HC had been already reported by Eason *et al.* in a Melanesian kindred in 1990.<sup>18</sup> In this same population, Arden *et al.*<sup>19</sup> have later linked the HC phenotype to the NI44T gain-of-function mutation of FPN1.

**Ferroportin biology and physiology and FD**

FPN1, the product of the *FPN1 (SLC40A1)* gene, transfers iron from the external milieu (i.e. maternal blood or intestinal lumen) and from internal sites of iron storage and recycles it into the bloodstream. In fact, it is highly expressed in liver and spleen macrophages, the luminal site of enterocytes and placental syncytiotrophoblasts.<sup>2-4</sup>

FPN1 is regulated at different levels by a number of factors, including transcriptionally by heme,<sup>20</sup> translationally by the iron-regulatory proteins (IRPs),<sup>21</sup> and posttranslationally mainly by hepcidin, the iron hormone. Hepcidin

is produced by the liver in response to iron, inflammation, and a variety of stressors.<sup>22-25</sup> Hepcidin binds to the extracellular loop of FPN1 and triggers its ubiquitinylation on lysine residues located in the intracellular domain leading to internalization and degradation in lysosomes.<sup>26-28</sup> This mechanism allows a finely-tuned control of iron efflux from enterocytes and macrophages toward the bloodstream when more iron is needed during active erythropoiesis (in this case, hepcidin synthesis is inhibited by erythroid signals), or blood iron must be controlled due to pathogen proliferation/growth or incipient iron overload (here hepcidin synthesis is induced by inflammatory or iron mediators, respectively) (reviewed by Drakesmith, Nemeth and Ganz<sup>29</sup>).

FPN1 topology and membrane organization have long been addressed with controversial results concerning localization of the N- and C-terminal extremities and number of transmembrane segments.<sup>30-39</sup> Recently, an inward-open conformation of the transporter has been predicted,<sup>34,37</sup> with a cluster of residues lying in the central core of the protein important for iron traffic and consistent with an iron-binding site<sup>37</sup> and residues involved in hepcidin binding fully accessible in the outward-open model.<sup>37</sup> The inward-open form may represent the resting state of the protein, and the outward-open state as a conformation attainable only in the presence of intracellular iron, i.e. when FPN1 shuttles between the two conforma-

**Table 2. Main features of Ferroportin Disease and other hereditary iron overload disorders in humans.**


Disorder	Affected gene (symbol / location)	Known or postulated gene product function	Epidemiology	Genetics	Mechanism for increased cellular iron deposits	Clinical onset (decade)	Main clinical manifestation	Clinical course	
I. Ferroportin Disease	Solute carrier family 40 (iron-regulated transporter), member 1	Iron exporter (SLC40A1 / 2q32) from cells including macrophages, enterocytes, syncytiotrophoblasts	Affects Caucasians and non Caucasians	Autosomal dominant	Iron retention due to decreased iron export	Any	<ul style="list-style-type: none"> <li>• Liver disease</li> <li>• Marginal anemia</li> </ul>	Mild	
II. Hemochromatosis	Hemochromatosis gene (HFE / 6p21.3)	Hepcidin regulator	Affects Caucasians of North European descent	Autosomal recessive	Increased iron accumulation in parenchymal cells due to increased transferrin and non-transferrin bound iron import	4 <sup>th</sup> -5 <sup>th</sup>	<ul style="list-style-type: none"> <li>• Liver Disease</li> <li>• Arthropathy</li> <li>• Cardiomyopathy</li> <li>• Endocrinopathy</li> </ul>	Mild-severe	
	Transferrin-receptor 2 (TfR2 / 7q22)	Hepcidin regulator	Affects Caucasians and non Caucasians			3 <sup>rd</sup> -4 <sup>th</sup>			
	Solute carrier family 40 (iron-regulated transporter), member 1 (SLC40A1 / 2q32)	Iron exporter from cells including macrophages, enterocytes, syncytiotrophoblasts	Affects Caucasians and non Caucasians	Autosomal dominant		4 <sup>th</sup> -5 <sup>th</sup>			
	Hepcidin antimicrobial peptide (HAMP / 19q13.1)	Degradation of ferroportin and downregulation of iron efflux from cells	Affects Caucasians and non Caucasians	Autosomal recessive		2 <sup>nd</sup> -3 <sup>rd</sup>		<ul style="list-style-type: none"> <li>• Hypogonadism and cardiomyopathy</li> <li>• Liver disease</li> </ul>	Severe
	Hemojuvelin (HJV / 1p21)	Hepcidin regulator	Affects Caucasians and non Caucasians						
III. Aceruloplasminemia	Ceruloplasmin (CP / 3q23-q25)	Iron efflux from cells	Affects Caucasians and non Caucasians	Autosomal recessive	Decreased iron efflux	2 <sup>nd</sup> -3 <sup>rd</sup>	<ul style="list-style-type: none"> <li>• Neurological manifestations</li> <li>• Anemia</li> </ul>	Severe	
IV. A (hypo)transferrinemia	Transferrin (Tf / 3q21)	<ul style="list-style-type: none"> <li>• Iron transport in the bloodstream</li> </ul>	Affects Caucasians and non Caucasians	Autosomal recessive	Increased iron influx	1 <sup>st</sup> -2 <sup>nd</sup>	Anemia	Severe	

tions (Figure 1A). The selective binding of hepcidin to the outer-facing conformation would, therefore, guarantee that FPN1 degradation can occur only when intracellular iron is abundant<sup>37</sup> and actively pumped through the channel<sup>38</sup> (Figure 1B). Recently, the crystal structures of a bacterial homolog of FPN1, BbFPN, has been resolved in both the outward- and inward-facing states, and a homology model with human FPN1 has been developed.<sup>39</sup> According to the Au, FPN1 has 12 TM helices, as previously predicted,<sup>32</sup> and is divided into two halves, one forming the N lobe, the other the C lobe connected by a long cytosolic loop, with a central cavity between the lobes that is open towards the extracellular side and not accessible from the intracellular side (Figure 1A). FPN1 undergoes an intra-domain conformational rearrangement during the transport cycle. When hepcidin enters the central cavity

between the N and C lobes, and interacts with the hepcidin-binding site located on the C lobe, it elicits two effects: a) it increases the accessibility of the intracellular loops that harbor the ubiquitination sites to the ubiquitin ligases; and b) it arrests the conformational transition of FPN1 from the outward-facing state to the inward-facing state, inhibiting the access of iron from the cytoplasm to the substrate-binding site within the intracellular gate (Figure 1B).<sup>39</sup>

**Molecular pathogenesis**

The general pathophysiological basis of FD is well defined and relies on the impaired iron export from the iron storage/recycling site (particularly macrophages) towards the bloodstream. Figure 2 shows the basic iron transport defect of the FD as opposed to FPN1-associated



**Figure 1. Biology of ferroportin and postulated pathobiology of Ferroportin Disease (FD).** (A) Structure-function relationship of iron-export ferroportin activity.<sup>39</sup> (B) Putative mechanisms of hepcidin binding to FPN and its degradation.<sup>39</sup> (C) Postulated basis for FD. (Upper panel) In cells undergoing relatively low iron flux, such as enterocytes, the product of the *FPN* wild-type allele is able to reach the plasma membrane and export iron. For clarity, mutated FPN1 was not depicted at the cell surface: based on previous *in vitro* work, it has been postulated that some mutant FPN1 can still reach the cell surface and preserve some iron-transport competence, but this is still controversial. (Lower panel) In cells undergoing high iron turnover, such as macrophages, increased requests for iron export impose high demands on FPN traffic leading to a 'traffic jam' within the endocytic/plasmamembrane and degradation compartments and inappropriately low wild-type allele product targeting to the cell membrane.<sup>54</sup> (D) Postulated effect of *FPN* mutations that affect formation of the intracellular gate and access to the iron binding site.<sup>39</sup>

HC. In the latter cases, as discussed above, mutations that affect the hepcidin binding site and/or FPN1 ubiquitination result in reduced FPN 'sensitivity' to hepcidin, leading to the FPN1-related HC phenotype. This has been nicely exemplified by an informative murine model corresponding to the mutation of the hepcidin binding site.<sup>40</sup>

In spite of these advances, the molecular pathogenesis of FD has long been elusive. A number of *in vitro* studies, mostly using over-expressed exogenous wild-type and mutant FPN1 in a variety of cell lines, have investigated FPN1 biology and function and the effect of different FPN1 mutants on protein traffic and iron-transfer capability, although with conflicting results, depending on the cell line or methodology used.<sup>30-32,34,35,38,41-47</sup>

In this context, it has been actively debated whether FPN1 haplo-insufficiency would explain FD or whether the disease results from a dominant-negative effect. It has been argued that if haplo-insufficiency was the explanation for FD, then nonsense mutations should also result in the disorder; however, so far, the vast majority of reported mutations in FD are missense mutations.<sup>48</sup> In addition, a targeted gene deletion in the murine *Fpn1* gene has little effect in heterozygous animals,<sup>49</sup> whereas the flatiron (*ffe*) mouse with a missense mutation in *Fpn1* that affects its localization and iron export activity when over-expressed *in vitro*, present a phenotype similar to human patients.<sup>50</sup> In studies using exogenous tagged protein *in vitro*, *Fpn1* forms multimers and mutant *Fpn1* prevents cell membrane localization of wild-type *Fpn1*.<sup>33,42,50</sup> A multimeric protein, through a dominant-negative effect, would better explain the autosomal dominant trait of FD. However, other studies from different groups have provided experimental evidence to support the opposite conclusion and showed that *Fpn1* is a monomer in cultured cells<sup>35,51,52</sup> and *in vivo*.<sup>53</sup> More recently, Sabelli *et al.*,<sup>54</sup> using for the first time cultured macrophages from FD patients, found that endogenous FPN1 shows a similar localization to that in donor macrophages, except for greater accumulation in lysosomes, suggesting a higher degradation rate of mutant FPN1. Unexpectedly, and contrary to previous studies using over-expressed mutant protein in cell lines, FPN1 in FD macrophage circulates in the early endocytic compartment, does not multimerize, it reaches the plasma membrane, is iron-transport competent (although to a lesser extent than normal macrophages), and is promptly internalized and degraded upon exposure to hepcidin. However, when FD macrophages are exposed to large amounts of heme iron, in contrast to donor macrophages, FPN1 can no longer reach the cell surface, leading to marked intracellular iron retention. Based on these observations, a model of FD has been proposed in which FPN1 monomers, in spite of the fact that half proteins are mutated, can still reach the cell surface and export iron in cells that are exposed *in vivo* to a relatively low flux of iron, such as enterocytes (Figure 1C).<sup>54</sup> On the contrary, in cells undergoing high iron turnover *in vivo*, such as tissue macrophages, sufficient FPN1 is prevented from reaching the plasma membrane, possibly due to a 'traffic jam' in the degradation and/or endocytic cycling pathways. This model is consistent with the clinical manifestation of FD characterized by early iron accumulation in hepatic Kupffer cells and normal transferrin saturation, indicating that mutant FPN1 activity does not limit intestinal iron transfer; the latter becomes critically low in young females at menarche or after aggressive phlebotomy, when high

iron demands for erythropoiesis likely impose increased FPN1 traffic/cycling within tissue macrophages.<sup>1,16,17</sup> (See below under Clinical Manifestations and Diagnosis and Treatment). This study did not address the question as to whether mutant or only wild-type FPN1 reaches the plasma membrane and whether mutant-FPN1 is transport competent. Previous studies have not been conclusive. Exogenously expressed p.A77D and p.Val162del FPN1 mutants have been found to be iron-transport incompetent in all studies, but able to reach the cell membrane in some,<sup>34,35,38,41,43</sup> and not in others.<sup>30,31</sup> The p.G80S FPN1 mutant has been localized at the cell surface in two published studies,<sup>45,55</sup> and found iron transport competent in one<sup>55</sup> and incompetent in the other.<sup>43</sup>

According to Taniguchi *et al.*,<sup>39</sup> the mutation sites associated with FD are mainly mapped onto the inter-lobe interface, mostly on the intracellular side, and form the intracellular gate. These mutations would, therefore, destabilize the inter-lobe interactions, thereby affecting the stable formation of the intracellular gate and reducing the iron transport activity of FPN1 (Figure 1D). It is possible that different mutants differently affect iron transport capability of FPN1; while this may be better overcome by the normal allele product in cells with low iron turnover such as enterocytes or hepatocytes, it may be further hampered in cells like macrophages where the additional 'traffic jam' in the endocytic-plasmamembrane compartment will aggravate the basic defect (see above).

### Genetics and epidemiology

A list of published mutations associated with FD and FPN1-related HC is reported in Table 3.<sup>5-8,17,43,56-102</sup> Numerous mutations of the *FPN1* gene have been identified so far in probands with the classic FD phenotype of French-Canadian, Melanesian, Thai, Japanese and European heritages.

A few common FPN1 mutations have been reported in independent pedigrees, in different countries (e.g. Val192del;<sup>56,60,72-79,92</sup> A77D,<sup>17,59,60</sup> G80S.<sup>43,55,56,61-63</sup> It is now believed that the most frequently reported FPN1 mutations, such as the p.Val162del, are more frequently identified than other SLC40A1 mutations because they have occurred multiple times in isolated populations rather than occurring once and spreading to different populations, as indicated by the identification of a *de novo* p.Val162del variant in an isolated case of FD.<sup>79</sup>

FPN1 variants are highly prevalent in African populations. The first prevalent FPN1 variant reported in Africans and Black Americans was the common Q248H polymorphism (p.Gln248His).<sup>92,93,100-102</sup> Interestingly, global analysis of variants in the SLC40A1 gene (which includes mutations associated with both the FD and FPN1-associated HH) revealed an allele frequency of 0.0364%, giving a predicted pathogenic genotype carrier rate of 1 in 1373, a figure that approaches the frequency of HFE-HC.<sup>105</sup> This was largely due to the relatively high allele frequencies for two SLC40A1 variants (p.Asp270Val<sup>84,85</sup> and p.Arg371Trp<sup>56</sup>) in the African populations; the predicted SLC40A1 pathogenic genotype carrier rate of these two variants is 1 in 197 among the African population.<sup>105</sup> The Q248H,<sup>101,102</sup> the p.Asp270Val and the p.Arg371Trp and other FPN1 polymorphic variants<sup>84</sup> may also predispose to iron overload; but no clear evidence for this has been provided (e.g. lack of functional studies), while the possibility remains that, because of the small sample size, these observations could

Table 3. Disease-associated mutations of the FPN1 gene.

Gene SLC40A1 (RefSeq NM_014585.5, NP_055400.1)					
A. Ferroportin disease					
	Nucleotide change	Amino acid change	Type of variation*	Phenotype	Reference
1.	c.134C>A	p.Ala45Glu	Missense	ferroportin disease <sup>a</sup>	56
2.	c.205G>A	p.Ala69Thr	Missense	ferroportin disease	57
3.	c.206C>T	p.Ala69Val	Missense	ferroportin disease <sup>a</sup>	56
4.	c.212C>T	p.Ser71Phe	Missense	ferroportin disease <sup>a</sup>	56
5.	c.214G>T	p.Val72Phe	Missense	ferroportin disease	58
6.	c.230C>A	p.Ala77Asp	Missense	ferroportin disease	17,59,60
7.	c.238G>A	p.Gly80Ser	Missense	ferroportin disease	43,55,56,61-63
8.	c.239G>T	p.Gly80Val	Missense	ferroportin disease	64
9.	c.252C>G	p.Asp84Glu	Missense	ferroportin disease	91
10.	c.262A>G	p.Arg88Gly	Missense	ferroportin disease	56, 65
11.	c.263G>C	p.Arg88Thr	Missense	ferroportin disease	66
12.	c.386T>C	p.Leu129Pro	Missense	ferroportin disease	67
13.	c.454A>T	p.Ile152Phe	Missense	ferroportin disease	68
14.	c.469G>A	p.Asp157Asn	Missense	ferroportin disease	58
15.	c.469G>T	p.Asp157Tyr	Missense	ferroportin disease	69
16.	c.470A>C	p.Asp157Ala	Missense	ferroportin disease	70
17.	c.470A>G	p.Asp157Gly	Missense	ferroportin disease	56,69,71
18.	c.473G>T	p.Trp158Leu	Missense	ferroportin disease	56
19.	c.474G>T	p.Trp158Cys	Missense	ferroportin disease	47
20.	c.484_486del	p.Val162del	Deletion	ferroportin disease	56,60,72-79,92
21.	c.521A>T	p.Asn174Ile	Missense	ferroportin disease	61
22.	c.532C>G	p.Arg178Gly	Missense	ferroportin disease	77
23.	c.533G>A	p.Arg178Gln	Missense	ferroportin disease	56,65
24.	c.539T>C	p.Ile180Thr	Missense	ferroportin disease	66
25.	c.542A>T	p.Asp181Val	Missense	ferroportin disease	56,64,69
26.	c.546G>T	p.Gln182His	Missense	ferroportin disease	56, 71
27.	c.553A>G	p.Asn185Asp	Missense	ferroportin disease	56, 80
28.	c.554A>C	p.Asn185Thr	Missense	ferroportin disease <sup>a</sup>	56
29.	c.610G>A	p.Gly204Ser	Missense	ferroportin disease <sup>a</sup>	56
30.	c.689C>A	p.Thr230Asn	Missense	ferroportin disease <sup>a</sup>	69
31.	c.695C>A	p.Ala232Asp	Missense	ferroportin disease	81
32.	c.698T>C	p.Leu233Pro	Missense	ferroportin disease	68,69
33.	c.744G>T	p.Gln248His	Missense	ferroportin disease <sup>a</sup>	82,83,100-102
34.	c.797T>C	p.Met266Thr	Missense	ferroportin disease <sup>a</sup>	69
35.	c.800G>A	p.Gly267Asp	Missense	ferroportin disease	64
36.	c.809A>T	p.Asp270Val	Missense	ferroportin disease	84,85
37.	c.968G>T	p.Gly323Val	Missense	ferroportin disease	71
38.	c.1035G>C	p.Leu345Phe	Missense	ferroportin disease <sup>a</sup>	69
39.	c.1051A>G	p.Ile351Val	Missense	ferroportin disease <sup>a</sup>	69
40.	c.1111C>T	p.Arg371Trp	Missense	ferroportin disease <sup>a</sup>	56
41.	c.1112G>A	p.Arg371Gln	Missense	ferroportin disease <sup>a</sup>	56
42.	c.1328C>T	p.Pro443Leu	Missense	ferroportin disease <sup>a</sup>	69
43.	c.1402G>A	p.Gly468Ser	Missense	ferroportin disease <sup>a</sup>	86
44.	c.1466G>A	p.Arg489Lys	Missense	ferroportin disease	46
45.	c.1467A>C	p.Arg489Ser	Missense	ferroportin disease	87
46.	c.1468G>A	p.Gly490Ser	Missense	ferroportin disease	56,65,69
47.	c.1469G>A	p.Gly490Asp	Missense	ferroportin disease	88, 69
48.	c.1520A>G	p.His507Arg	Missense	ferroportin disease <sup>a</sup>	89
49.	c.1681A>G	p.Arg561Gly	Missense	ferroportin disease <sup>a</sup>	90

continued on the next page

continued from the previous page

B. Ferroportin1-associated hemochromatosis					
1.	c.-59_-45del		Deletion (heterozygous state)	hemochromatosis	65
2.	c.190T>A	p.Tyr64Asn	Missense (heterozygous state)	hemochromatosis <sup>b</sup>	93
3.	c.190T>C	p.Tyr64His	Missense (heterozygous state)	hemochromatosis	94
4.	c.430A>C	p.Asn144His	Missense (heterozygous state)	hemochromatosis <sup>b</sup>	5
5.	c.430A>G	p.Asn144Asp	Missense (heterozygous state)	hemochromatosis <sup>b</sup>	6
6.	c.431A>C	p.Asn144Thr	Missense (heterozygous state)	hemochromatosis <sup>b</sup>	19
7.	c.718A>G	p.Lys240Glu	Missense (heterozygous state)	hemochromatosis	95
8.	c.977G>A	p.Cys326Tyr	Missense (heterozygous state)	hemochromatosis	96, 97
9.	c.977G>C	p.Cys326Ser	Missense (heterozygous state)	hemochromatosis <sup>b</sup>	7
10.	c.977G>T	p.Cys326Phe	Missense (heterozygous state)	hemochromatosis <sup>b</sup>	8
11.	c.1014T>G	p.Ser338Arg	Missense (heterozygous state)	hemochromatosis <sup>b</sup>	98
12.	c.1502A>G	p.Tyr501Cys	Missense (heterozygous state)	hemochromatosis	99
13.	c.1510G>A	p.Asp504Asn	Missense (heterozygous state)	hemochromatosis	69
14.	c.1520A>G	p.His507Arg	Missense (heterozygous state)	hemochromatosis <sup>b</sup>	47

\*All reported ferroportin mutations are at the heterozygous state (autosomal dominant trait). <sup>a</sup>Reported data do not allow a classic Ferroportin Disease phenotype to be assigned. <sup>b</sup>Patients carrying a ferroportin missense mutation in whom a classic hemochromatosis phenotype is confirmed by a liver biopsy.

be attributable to chance or that the polymorphisms identified may be in linkage disequilibrium with other disease-causing loci. Yet, taken together, the collected data make FPN1 the gene most frequently associated with hereditary hyperferritinemia in Africans.

### Clinical manifestations and diagnosis

As discussed, FD is caused by loss-of-function mutations in FPN1. These mutations impair iron export, particularly from reticuloendothelial macrophages. The result is iron accumulation in macrophages of the spleen, liver, and bone (reflected by high levels of SF) (Figure 3). At liver histology, parenchymal cells of these organs are largely spared (Figure 3), but discrete hepatocytic iron deposits are also appreciable, due to defective FPN1 activity in hepatocytes, even at early stages.<sup>16</sup> Clinical presentation appears heterogeneous, but overall expressivity is milder than classic HC, and the associated liver disease is usually not as severe (Table 2 and Figure 3).<sup>1,16,17,56</sup> As occurs in classic forms of HFE HC, also in the FD host factors (menses, blood loss, etc.), co-inheritance of mutations of other iron-genes or variants in genes associated to antioxidant defense and organ fibrosis, and associated pathological conditions (metabolic syndrome, viral hepatitis, etc.) may all affect the phenotype. Hypochromic anemia is not uncommon in young menstruating females.

Owing to the mild clinical expressivity reported in the literature, doubts have been raised on the penetrance of the genetic defect and the rationale for iron-removal therapy. However, there is limited and usually not detailed clinical information in the published reports; this, and the lack of prospective studies, still hamper our understanding of the actual clinical impact of the disorder. In the only report published so far, 6 members of the pedigree in which FD was first described<sup>16</sup> were followed for 11-24 years.<sup>104</sup> The proband, aged 83, who had carried an occult HBV infection since the age of 56, developed a liver cancer in a non-cirrhotic liver after discontinuation of a 20-year long phlebotomy program; 2 siblings, who had also interrupted treatment, showed a fibrosis progression. These

clinical data, while of interest, do not allow definite conclusions to be drawn as to a pathogenic link between iron accumulation in FD and liver damage and disease.

The hallmark of classic FD is marked iron accumulation in Kupffer cells (Figure 3). Kupffer cells are vital to the production of fibrogenic mediators, to immunological tumor surveillance, and disposal of transformed hepatocytes.<sup>105</sup> Selective and massive iron overload may impair these activities and favor fibrogenesis and carcinogenesis. Moreover, as discussed above, hepatocytic iron accumulation also takes place in FD, although to a much lesser extent than in HFE- and non-HFE HC, and the established pro-oxidant damaging activity of iron in parenchymal cells may also contribute to disease progression.

Unlike HFE-HC, the pattern of inheritance of FD is autosomal dominant. Therefore, either parent carries the pathogenic mutation of FPN1 and presents with unexplained hyperferritinemia. In addition, the proband carries a 50% risk of having an affected child. The disease must be suspected in any individual with unexplained hyperferritinemia and low-normal transferrin saturation (TS), or non-parenchymal cell siderosis at liver biopsy or liver and spleen iron accumulation at MRI (Table 4).

Hyperferritinemia in FD appears very early in life, and unexplained hyperferritinemia with normal TS in a child should prompt MRI evaluation to evaluate iron accumulation in liver, spleen and bone marrow<sup>106</sup> (see below).

Figure 4 shows a proposed algorithm for the diagnosis of FD. If hyperferritinemia associates with high TS (as confirmed in at least two sequential determinations) but in the absence of anemia, a typical picture of HFE- and non HFE-HC (including FPN1-associated HC due to gain-of-function FPN1 mutations) is ruled out *a priori*. If hyperferritinemia associates with high TS and anemia, a typical picture of hereditary hemoglobinopathies and red cell defects or atransferrinemia, FD is again ruled out (Figure 4).

On the contrary, in subjects with increased serum ferritin and low or normal TS, the workup should focus on common causes of secondary hyperferritinemia and other rare causes of hereditary hyperferritinemia to confirm the




Figure 2. The basis for abnormal iron transfer into the bloodstream in Ferroportin Disease as opposed to FPN-associated hereditary hemochromatosis.

diagnosis of FD (Figure 4). First, common causes of hyperferritinemia, such as metabolic disorders, inflammation, cancer, etc., should be considered. If they are not found, or if the hyperferritinemia persists after their treatment, the next step depends on whether or not anemia is present. In the absence of overt anemia, if liver and spleen iron content are increased at MRI or liver biopsy shows prominent Kupffer cell iron load, FD disease should be considered and genetic testing performed for confirmation of diagnosis (Figure 4). Another common cause of hereditary hyperferritinemia with normal TS associated with iron accumulation and anemia is Gaucher disease, usually associated with hepatosplenomegaly, cytopenia, abnormal coagulation, bone disease, and neuropathic manifestations.<sup>107</sup>

In the absence of body iron accumulation, but in the presence of elevated SF levels and normal TS, autosomal dominant hyperferritinemia with cataract (due to mutations of the iron responsive element in the 5' untranslated region of the L ferritin mRNA<sup>108</sup>) or without cataract,<sup>109</sup> should be considered. If overt anemia is present, but TS is normal/low, aceruloplasminemia should be suspected, a rare autosomal recessive disease due to loss of function

mutations in ceruloplasmin (CP) and resulting in iron overload in the liver and pancreas, and progressive neurodegeneration, diabetes and retinal degeneration.<sup>110</sup>

Brain MRI with typical iron accumulation in basal ganglia and thalamus may help confirm the diagnosis. As mentioned above, another rare genetic disease presenting with hyperferritinemia and anemia is atransferrinemia/hypotransferrinemia<sup>111</sup> which, however, is characterized by increased transferrin saturation due to extremely low serum transferrin levels.

Differential diagnosis mainly includes the classic (HFE) and non-classic (TfR2, HAMP, HJV and FPN1) forms of HH, all characterized by early and progressive increase of TS followed by elevation of serum ferritin as iron accumulation increases in parenchymal cells of the liver, pancreas, heart and other organs (Table 2). As discussed, unlike HH, in FD clinical expressivity is milder.

Abdominal MRI is a useful non-invasive tool to categorize and diagnose the disorder, as it can differentiate patients with FD, characterized by the SSL triad (spleen, spine, liver) iron retention (Figure 5B), from all other forms of HH, including FPN1-HC, associated with liver iron



overload but normal spleen and bone marrow iron content (Figure 5D).<sup>112</sup>

**Treatment**

Venesection is the cornerstone of therapy also in FD, but it may not be tolerated equally in all patients, and low TS with anemia may be rapidly established despite SF still being elevated.<sup>1</sup> Macrophage iron overload is very resistant to iron withdrawal in this disorder, even in patients who are apparently well-treated (Figure 5C). Therefore, unlike HH, not only serum ferritin, but especially TS should be carefully monitored during therapy. In addition, therapy should not aim at reaching the usual HH targets for iron depletion (TS below 20%, SF 50 ng/L or slight anemia) but be more conservative. There are no studies on the optimal phlebotomy schedule in FD. In practical

terms, a monthly/bi-monthly phlebotomy session for 1-2 years, depending on the underlying mutation, allows an acceptable state of iron depletion to be reached, while maintenance therapy (usually a phlebotomy session every 4-6 months) should be continued for life. A reasonable target for therapy is an SF level of 100-200 ng/mL. In certain cases, such Ft values may still reflect some iron loading of tissue macrophages (Figure 5C), but the associated clinical risk is negligible. Ideally, the optimal target is the lowest acceptable ferritin level for TS and hemoglobin levels not below the lower limit of normal. The (controversial) dietary restrictions sometimes recommended for patients with HH (avoiding vitamin C or iron-rich or enriched foods) do not apply to FD due to the different pathogenic basis as compared to HH: normal/sufficient enterocyte iron absorption and normal/marginally increased iron




Figure 3. The different stages and outcomes of “iron retention” in Ferroportin Disease versus “iron accumulation” in FPN1-associated hemochromatosis (HC). Liver histology pictures are reproduced with the permission of Sabelli et al.<sup>54</sup>

Table 4. Suspecting and diagnosing Ferroportin Disease.

Sex	Ethnicity	Age, y	When to suspect Signs	Essential for diagnosis
Either	Any	10-80	<ul style="list-style-type: none"> <li>• Unexplained hyperferritinemia and normal or inappropriately low transferrin saturation</li> <li>• Isolated hyperferritinemia in father or mother</li> <li>• Sinusoidal (Kupffer cell) iron overload at liver biopsy or spleen (and liver), iron accumulation at MRI in patients with unexplained hyperferritinemia and normal or inappropriately low transferrin saturation</li> </ul>	Heterozygosity for <i>FPN</i> mutation and hyperferritinemia with normal or inappropriately low transferrin saturation and Kupffer cell iron overload at liver biopsy

y: years; MRI: magnetic resonance imaging.

accumulation in parenchymal cells in the FD *versus* increased iron absorption and marked iron accumulation in parenchymal cells in HH.

Iron chelation may be an option in selected cases.<sup>79</sup>


Siblings of patients with FD, like their offspring, must undergo screening since they have a 50% chance of being susceptible.

**Conclusions**


FPN1 is a multipass membrane iron-exporter that has evolved in mammals to assure sufficient iron delivery from the external milieu and internal sites of iron storage and recycling to the bloodstream, mainly to support the erythron activity. Overall, the *FPN1/SLC40A1* gene is essential for humans and total loss (homozygote muta-

tion) of its product is incompatible with life.<sup>49</sup> Loss-of-function of one FPN1 allele in humans results in FD, characterized by a preserved intestinal iron export activity but compromised iron export from tissue macrophages. This leads to progressive iron retention in liver, spleen and bone marrow macrophages, resulting in inappropriately low iron delivery to circulating transferrin and marginal iron-restricted erythropoiesis that may result in overt anemia when bone marrow demands are increased (e.g. menarche, aggressive phlebotomy regimen). Gain-of-function mutations of FPN1 preclude the inhibitory activity of hepcidin, thereby leading to unrestricted iron transfer to the bloodstream and causing a rare form of HH.

The pathogenic, biochemical and clinical signatures of FD are symmetrical and opposite to HFE and non HFE-HH: normal/sufficient enterocyte iron absorption, marked iron accumulation in non parenchymal cells in



**Figure 4.** Diagnostic algorithm for Ferroportin Disease and hereditary hyperferritinemia. ACD/AI: anemia of chronic disease/anemia of inflammation. \*Gaucher disease may present with or without siderosis depending on the disease stage. \*\*Advanced ACD/AI may also present with siderosis at MRI (usually spleen and bone marrow).



**Figure 5. Abdominal magnetic resonance imaging (MRI) pattern of Ferroportin Disease (FD).** MRI scans. T2\*-weighted gradient-echo sequences were used to detect iron accumulation. (A) Normal subject. (B) FD. (C) FD after completion of phlebotomy program (note that excess iron is still detectable in the liver and spine in spite of normal serum ferritin and transferrin saturation levels). (D) Ferroportin-associated hereditary hemochromatosis: iron accumulation involves only the liver and spares the spleen and spine (arrows).

the FD *versus* increased iron absorption and marked iron accumulation in parenchymal cells in HH; hyperferritinemia with normal/low transferrin saturation in FD *versus* hyperferritinemia and high transferrin saturation in HH; intolerance to aggressive phlebotomy regimens in FD *versus* optimal response to intense phlebotomy in HH; mild and benign clinical course in FD *versus* potentially severe clinical expressivity in HH; vertical hereditary transmission and presentation at each generation of FD *versus* recessive transmission of most forms of HH (except FPN1-HH).

While the molecular pathogenesis of FD is becoming more and more defined, the long-term effect of massive iron retention in tissue macrophages in the setting of chronic inflammatory/infectious or degenerative disorders is still unclear.

Today, isolated or unexplained hyperferritinemia represents one of the commonest reasons for referral. Knowing that FD is one of the most frequent genetic causes of hyperferritinemia, regardless of ethnicity, it is important to maintain a high diagnostic suspicion for this disorder.

## References

- Pietrangelo A. The ferroportin disease. *Blood Cells Mol Dis.* 2004;32(1):131-138.
- Abboud S, Haile DJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. *J Biol Chem.* 2000;275(26):19906-19912.
- Donovan A, Brownlie A, Zhou Y, et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. *Nature.* 2000;403(6771):776-781.
- McKie AT, Marciani P, Rolfs A, et al. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. *Mol Cell.* 2000;5(2):299-309.
- Njajou OT, Vaessen N, Joosse M, et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. *Nat Genet.* 2001;28(3):213-214.
- Wallace DF, Clark RM, Harley HA, Subramaniam VN. Autosomal dominant iron overload due to a novel mutation of ferroportin1 associated with parenchymal iron loading and cirrhosis. *J Hepatol.* 2004;40(4):710-713.
- Sham RL, Phatak PD, West C, Lee P, Andrews C, Beutler E. Autosomal dominant hereditary hemochromatosis associated with a novel ferroportin mutation and unique clinical features. *Blood Cells Mol Dis.* 2005;34(2):157-161.
- Chen SR, Yang LQ, Chong YT, et al. Novel gain of function mutation in the SLC40A1 gene associated with hereditary haemochromatosis type 4. *Intern Med J.* 2015;45(6):672-676.
- Brissot P, Loreal O. Iron metabolism and related genetic diseases: A cleared land, keeping mysteries. *J Hepatol.* 2016;64(2):505-515.
- Hollerer I, Bachmann A, Muckenthaler MU. Pathophysiological consequences and benefits of HFE mutations: 20 years of research. *Haematologica.* 2017;102(5):809-817.
- Pietrangelo A. Hemochromatosis: an endocrine liver disease. *Hepatology.* 2007;46(4):1291-1301.
- Feder JN, Gnirke A, Thomas W, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. *Nat Genet.* 1996;13(4):399-408.
- Camaschella C, Roetto A, Cali A, et al. The gene TFR2 is mutated in a new type of haemochromatosis mapping to 7q22. *Nat Genet.* 2000;25(1):14-15.
- Rivard SR, Lanzara C, Grimard D, et al. Juvenile hemochromatosis locus maps to chromosome 1q in a French Canadian population. *Eur J Hum Genet.* 2003;11(8):585-589.
- Papanikolaou G, Samuels ME, Ludwig EH, et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. *Nat Genet.* 2004;36(1):77-82.
- Pietrangelo A, Montosi G, Totaro A, et al. Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene [see comments]. *N Engl J Med.* 1999;341(10):725-732.
- Montosi G, Donovan A, Totaro A, et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. *J Clin Invest.* 2001;108(4):619-623.
- Eason RJ, Adams PC, Aston CE, Searle J. Familial iron overload with possible autosomal dominant inheritance. *Aust NZ J Med.* 1990;20:226-230.
- Arden KE, Wallace DF, Dixon JL, et al. A novel mutation in ferroportin1 is associated with haemochromatosis in a Solomon Islands patient. *Gut.* 2003;52(8):1215-1217.
- Marro S, Chiabrando D, Messina E, et al.

- Heme controls ferroportin1 (FPN1) transcription involving Bach1, Nrf2 and a MARE/ARE sequence motif at position -7007 of the FPN1 promoter. *Haematologica*. 2010;95(8):1261-1268.
21. Lymboussaki A, Pignatti E, Montosi G, et al. The role of the iron responsive element in the control of ferroportin1/IREG1/MTP1 gene expression. *J Hepatol*. 2003;39(5):710-715.
  22. Krause A, Neitz S, Magert HJ, et al. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. *FEBS Lett*. 2000;480(2-3):147-150.
  23. Pigeon C, Ilyin G, Courselaud B, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. *J Biol Chem*. 2001;276(11):7811-7819.
  24. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. *J Biol Chem*. 2001;276(11):7806-7810.
  25. Vecchi C, Montosi G, Zhang K, et al. ER stress controls iron metabolism through induction of hepcidin. *Science*. 2009;325(5942):877-880.
  26. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. *Science*. 2004;306(5704):2090-2093.
  27. Qiao B, Sugianto P, Fung E, et al. Hepcidin-induced endocytosis of ferroportin is dependent on ferroportin ubiquitination. *Cell Metab*. 2012;15(6):918-924.
  28. Ross SL, Tran L, Winters A, et al. Molecular Mechanism of Hepcidin-Mediated Ferroportin Internalization Requires Ferroportin Lysines, Not Tyrosines or JAK-STAT. *Cell Metab*. 2012;15(6):905-917.
  29. Drakesmith H, Nemeth E, Ganz T. Ironing out Ferroportin. *Cell Metab*. 2015;22(5):777-787.
  30. Schimanski LM, Drakesmith H, Merryweather-Clarke AT, et al. In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations. *Blood*. 2005;105(10):4096-4102.
  31. Drakesmith H, Schimanski LM, Ormerod E, et al. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. *Blood*. 2005;106(3):1092-1097.
  32. Liu XB, Yang F, Haile DJ. Functional consequences of ferroportin 1 mutations. *Blood Cells Mol Dis*. 2005;35(1):33-46.
  33. De Domenico I, Ward DM, Musci G, Kaplan J. Evidence for the multimeric structure of ferroportin. *Blood*. 2007;109(5):2205-2209.
  34. Wallace DF, Harris JM, Subramaniam VN. Functional analysis and theoretical modeling of ferroportin reveals clustering of mutations according to phenotype. *Am J Physiol Cell Physiol*. 2010;298(1):C75-84.
  35. Rice AE, Mendez MJ, Hokanson CA, Rees DC, Bjorkman PJ. Investigation of the biophysical and cell biological properties of ferroportin, a multipass integral membrane protein iron exporter. *J Mol Biol*. 2009;386(3):717-732.
  36. Le Gac G, Ka C, Joubrel R, et al. Structure-function analysis of the human ferroportin iron exporter (SLC40A1): effect of hemochromatosis type 4 disease mutations and identification of critical residues. *Hum Mutat*. 2013;34(10):1371-1380.
  37. Bonaccorsi di Patti MC, Polticelli F, Cece G, et al. A structural model of human ferroportin and of its iron binding site. *FEBS J*. 2014;281(12):2851-2860.
  38. Praschberger R, Schranz M, Griffiths WJ, et al. Impact of D181V and A69T on the function of ferroportin as an iron export pump and hepcidin receptor. *Biochim Biophys Acta*. 2014;1842(9):1406-1412.
  39. Taniguchi R, Kato HE, Font J, et al. Outward- and inward-facing structures of a putative bacterial transition-metal transporter with homology to ferroportin. *Nat Commun*. 2015;6:8545.
  40. Altamura S, Kessler R, Grone HJ, et al. Resistance of ferroportin to hepcidin binding causes exocrine pancreatic failure and fatal iron overload. *Cell Metab*. 2014;20(2):359-367.
  41. McGregor JA, Shayeghi M, Vulpe CD, et al. Impaired iron transport activity of ferroportin 1 in hereditary iron overload. *J Membr Biol*. 2005;206(1):3-7.
  42. De Domenico I, Ward DM, Nemeth E, et al. The molecular basis of ferroportin-linked hemochromatosis. *Proc Natl Acad Sci USA*. 2005;102(25):8955-8960.
  43. De Domenico I, McVey Ward D, Nemeth E, et al. Molecular and clinical correlates in iron overload associated with mutations in ferroportin. *Haematologica*. 2006;91(8):1092-1095.
  44. De Domenico I, Ward DM, Langelier C, et al. The molecular mechanism of hepcidin-mediated ferroportin down-regulation. *Mol Biol Cell*. 2007;18(7):2569-2578.
  45. Mayr R, Janecke AR, Schranz M, et al. Ferroportin disease: A systematic meta-analysis of clinical and molecular findings. *J Hepatol*. 2010;53(5):941-949.
  46. Griffiths WJ, Mayr R, McFarlane I, et al. Clinical presentation and molecular pathophysiology of autosomal dominant hemochromatosis caused by a novel ferroportin mutation. *Hepatology*. 2010;51(3):788-795.
  47. Mayr R, Griffiths WJ, Hermann M, et al. Identification of Mutations in SLC40A1 That Affect Ferroportin Function and Phenotype of Human Ferroportin Iron Overload. *Gastroenterology*. 2011;140(7):2056-2063 e2051.
  48. Pietrangelo A, Caleffi A, Corradini E. Non-HFE hepatic iron overload. *Sem Liv Dis*. 2011;31(3):302-318.
  49. Donovan A, Lima CA, Pinkus JL, et al. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. *Cell Metab*. 2005;1(3):191-200.
  50. Zohn IE, De Domenico I, Pollock A, et al. The flatiron mutation in mouse ferroportin acts as a dominant negative to cause ferroportin disease. *Blood*. 2007;109(10):4174-4180.
  51. Goncalves AS, Muzeau F, Blaybel R, et al. Wild-type and mutant ferroportins do not form oligomers in transfected cells. *Biochem J*. 2006;396(2):265-275.
  52. Schimanski LM, Drakesmith H, Talbott C, et al. Ferroportin: lack of evidence for multimers. *Blood Cells Mol Dis*. 2008;40(3):360-369.
  53. Pignatti E, Mascheroni L, Sabelli M, Barelli S, Biffo S, Pietrangelo A. Ferroportin is a monomer in vivo in mice. *Blood Cells Mol Dis*. 2006;36(1):26-32.
  54. Sabelli M, Montosi G, Garuti C, et al. Human macrophage ferroportin biology and the basis for the ferroportin disease. *Hepatology*. 2017;65(5):1512-1525.
  55. McDonald CJ, Wallace DF, Ostini L, Bell SJ, Demediuk B, Subramaniam VN. G80S-linked ferroportin disease: classical ferroportin disease in an Asian family and reclassification of the mutant as iron transport defective. *J Hepatol*. 2011;54(3):538-544.
  56. Le Lan C, Mosser A, Ropert M, et al. Sex and acquired cofactors determine phenotypes of ferroportin disease. *Gastroenterology*. 2011;140(4):1199-1207.e1-2.
  57. Ferbo L, Manzini PM, Badar S, et al. Detection of a rare mutation in the ferroportin gene through targeted next generation sequencing. *Blood Transfus*. 2016;14(6):531-534.
  58. Pelucchi S, Mariani R, Salvioni A, et al. Novel mutations of the ferroportin gene (SLC40A1): analysis of 56 consecutive patients with unexplained iron overload. *Clin Genet*. 2008;73(2):171-178.
  59. Subramaniam VN, Wallace DF, Dixon JL, Fletcher LM, Crawford DH. Ferroportin disease due to the A77D mutation in Australia. *Gut*. 2005;54(7):1048-1049.
  60. Lim FL, Dooley JS, Roques AW, Grellier L, Dhillon AP, Walker AP. Hepatic iron concentration, fibrosis and response to venesection associated with the A77D and V162del "loss of function" mutations in ferroportin disease. *Blood Cells Mol Dis*. 2008;40(3):328-333.
  61. Corradini E, Montosi G, Ferrara F, et al. Lack of enterocyte iron accumulation in the ferroportin disease. *Blood Cells Mol Dis*. 2005;35(3):315-318.
  62. Mougou A, Pietrangelo A, Caleffi A, Kourakli A, Karakantza M, Zoumbos N. G80S-linked ferroportin disease: the first clinical description in a Greek family. *Blood Cells Mol Dis*. 2008;41(1):138-139.
  63. Wolff F, Bailly B, Gulbis B, Cotton F. Monitoring of hepcidin levels in a patient with G80S-linked ferroportin disease undergoing iron depletion by phlebotomy. *Clin Chim Acta*. 2014;430:20-21.
  64. Cremonesi L, Forni GL, Soriani N, et al. Genetic and clinical heterogeneity of ferroportin disease. *Br J Haematol*. 2005;131(5):663-670.
  65. Cunat S, Giansily-Blaizot M, Bismuth M, et al. Global sequencing approach for characterizing the molecular background of hereditary iron disorders. *Clin Chem*. 2007;53(12):2060-2069.
  66. Bach V, Remacha A, Altes A, Barcelo MJ, Molina MA, Baiget M. Autosomal dominant hereditary hemochromatosis associated with two novel Ferroportin 1 mutations in Spain. *Blood Cells Mol Dis*. 2006;36(1):41-45.
  67. Moreno-Carralero MI, Munoz-Munoz JA, Cuadrado-Grande N, et al. A novel mutation in the SLC40A1 gene associated with reduced iron export in vitro. *Am J Hematol*. 2014;89(7):689-694.
  68. Girelli D, De Domenico I, Bozzini C, et al. Clinical, pathological, and molecular correlates in ferroportin disease: A study of two novel mutations. *J Hepatol*. 2008;49(4):664-671.
  69. Callebaut I, Joubrel R, Pissard S, et al. Comprehensive functional annotation of 18 missense mutations found in suspected hemochromatosis type 4 patients. *Hum Mol Genet*. 2014;23(17):4479-4490.
  70. Saja K, Bignell P, Robson K, Provan D. A novel missense mutation c.470 A>C (p.D157A) in the SLC40A1 gene as a cause of ferroportin disease in a family with hyperferritinaemia. *Br J Haematol*. 2010;149(6):914-916.
  71. Hetet G, Devaux I, Soufir N, Grandchamp B, Beaumont C. Molecular analyses of patients with hyperferritinemia and normal serum iron values reveal both L ferritin IRE and 3 new ferroportin (slc11a3) mutations. *Blood*.

- 2003;102(5):1904-1910.
72. Devalia V, Carter K, Walker AP, et al. Autosomal dominant reticuloendothelial iron overload associated with a 3-base pair deletion in the ferroportin 1 gene (SLC11A3). *Blood*. 2002;100(2):695-697.
  73. Wallace DF, Pedersen P, Dixon JL, et al. Novel mutation in ferroportin1 is associated with autosomal dominant hemochromatosis. *Blood*. 2002;100(2):692-694.
  74. Cazzola M, Cremonesi L, Papaioannou M, et al. Genetic hyperferritinaemia and reticuloendothelial iron overload associated with a three base pair deletion in the coding region of the ferroportin gene (SLC11A3). *Br J Haematol*. 2002;119(2):539-546.
  75. Melis MA, Cau M, Congiu R, et al. A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron. *Haematologica*. 2008;93(10):1473-1479.
  76. Roetto A, Merryweather-Clarke AT, Daraio F, et al. A valine deletion of ferroportin 1: a common mutation in hemochromatosis type 4. *Blood*. 2002;100(2):733-734.
  77. Speletas M, Kioumi A, Loules G, et al. Analysis of SLC40A1 gene at the mRNA level reveals rapidly the causative mutations in patients with hereditary hemochromatosis type IV. *Blood Cells Mol Dis*. 2008;40(3):353-359.
  78. Zoller H, McFarlane I, Theurl I, et al. Primary iron overload with inappropriate hepcidin expression in V162del ferroportin disease. *Hepatology*. 2005;42(2):466-472.
  79. Unal S, Piperno A, Gumruk F. Iron chelation with deferasirox in a patient with de-novo ferroportin mutation. *J Trace Elem Med Biol*. 2015;30:1-3.
  80. Morris TJ, Litvinova MM, Ralston D, Mattman A, Holmes D, Lockitch G. A novel ferroportin mutation in a Canadian family with autosomal dominant hemochromatosis. *Blood Cells Mol Dis*. 2005;35(3):309-314.
  81. Relvas L, Claro MT, Bento MC, Ribeiro ML. Novel human pathological mutations. Gene symbol: SLC40A1. Disease: haemochromatosis, type 4. *Hum Genet*. 2009;125(3):338.
  82. Gordeuk VR, Caleffi A, Corradini E, et al. Iron overload in Africans and African-Americans and a common mutation in the SLC40A1 (ferroportin 1) gene small star. *Blood Cells Mol Dis*. 2003;31(3):299-304.
  83. Beutler E, Barton JC, Felitti VJ, et al. Ferroportin 1 (SLC40A1) variant associated with iron overload in African-Americans. *Blood Cells Mol Dis*. 2003;31(3):305-309.
  84. Zaahl MG, Merryweather-Clarke AT, Kotze MJ, van der Merwe S, Warnich L, Robson KJ. Analysis of genes implicated in iron regulation in individuals presenting with primary iron overload. *Hum Genet*. 2004;115(5):409-417.
  85. Lee PL, Gaasterland T, Barton JC. Mild iron overload in an African American man with SLC40A1 D270V. *Acta Haematol*. 2012;128(1):28-32.
  86. Lee PL, Gelbart T, West C, Barton JC. SLC40A1 c.1402G-->a results in aberrant splicing, ferroportin truncation after glycine 330, and an autosomal dominant hemochromatosis phenotype. *Acta Haematol*. 2007;118(4):237-241.
  87. Koyama C, Wakusawa S, Hayashi H, et al. A Japanese family with ferroportin disease caused by a novel mutation of SLC40A1 gene: hyperferritinemia associated with a relatively low transferrin saturation of iron. *Intern Med*. 2005;44(9):990-993.
  88. Jouanolle AM, Douabin-Gicquel V, Halimi C, et al. Novel mutation in ferroportin 1 gene is associated with autosomal dominant iron overload. *J Hepatol*. 2003;39(2):286-289.
  89. Yamakawa N, Oe K, Yukawa N, et al. A Novel Phenotype of a Hereditary Hemochromatosis Type 4 with Ferroportin-1 Mutation, Presenting with Juvenile Cataracts. *Intern Med*. 2016;55(18):2697-2701.
  90. Sussman NL, Lee PL, Dries AM, Schwartz MR, Barton JC. Multi-organ iron overload in an African-American man with ALAS2 R452S and SLC40A1 R561G. *Acta Haematol*. 2008;120(3):168-173.
  91. Wallace DF, McDonald CJ, Ostini L, Iser D, Tuckfield A, Subramaniam VN. The dynamics of hepcidin-ferroportin internalization and consequences of a novel ferroportin disease mutation. *Am J Hematol*. 2017;92(10):1052-1061.
  92. Wallace DF, Browett P, Wong P, Kua H, Ameratunga R, Subramaniam VN. Identification of ferroportin disease in the Indian subcontinent. *Gut*. 2005;54(4):567-568.
  93. Rivard SR, Lanzara C, Grimard D, et al. Autosomal dominant reticuloendothelial iron overload (HFE type 4) due to a new missense mutation in the FERROPORTIN 1 gene (SLC11A3) in a large French-Canadian family. *Haematologica*. 2003;88(7):824-826.
  94. Raszeja-Wyszomirska J, Caleffi A, Milkiewicz P, Pietrangelo A. Ferroportin-related haemochromatosis associated with novel Y64H mutation of the SCL40A1 gene. *Prz Gastroenterol*. 2014;9(5):307-309.
  95. Del-Castillo-Rueda A, Moreno-Carralero ML, Alvarez-Sala-Walther LA, et al. Two novel mutations in the SLC40A1 and HFE genes implicated in iron overload in a Spanish man. *Eur J Haematol*. 2011;86(3):260-264.
  96. Viprakasit V, Merryweather-Clarke AT, Chinthammitr Y, et al. Molecular Diagnosis of the First Ferroportin Mutation (C326Y) in the Far East Causing a Dominant Form of Inherited Iron Overload. *Blood*. 2004;104(11):3204.
  97. Lok CY, Merryweather-Clarke AT, Viprakasit V, et al. Iron overload in the Asian community. *Blood*. 2009;114(1):20-25.
  98. Wallace DF, Dixon JL, Ramm GA, Anderson GJ, Powell LW, Subramaniam VN. A novel mutation in ferroportin implicated in iron overload. *J Hepatol*. 2007;46(5):921-926.
  99. Letocart E, Le Gac G, Majore S, et al. A novel missense mutation in SLC40A1 results in resistance to hepcidin and confirms the existence of two ferroportin-associated iron overload diseases. *Br J Haematol*. 2009;147(3):379-385.
  100. Barton JC, Acton RT, Rivers CA, et al. Genotypic and phenotypic heterogeneity of African Americans with primary iron overload. *Blood Cells Mol Dis*. 2003;31(3):310-319.
  101. Gordeuk VR, Diaz SF, Onojobi GO, et al. Ferroportin Q248H, dietary iron, and serum ferritin in community African-Americans with low to high alcohol consumption. *Alcohol Clin Exp Res*. 2008;32(11):1947-1953.
  102. Barton JC, Acton RT, Lee PL, West C. SLC40A1 Q248H allele frequencies and Q248H-associated risk of non-HFE iron overload in persons of sub-Saharan African descent. *Blood Cells Mol Dis*. 2007;39(2):206-211.
  103. Wallace DF, Subramaniam VN. The global prevalence of HFE and non-HFE hemochromatosis estimated from analysis of next-generation sequencing data. *Genet Med*. 2016;18(6):618-626.
  104. Corradini E, Ferrara F, Pollicino T, et al. Disease progression and liver cancer in the ferroportin disease. *Gut*. 2007;56(7):1030-1032.
  105. Manifold IH, Triger DR, Underwood JC. Kupffer-cell depletion in chronic liver disease: implications for hepatic carcinogenesis. *Lancet*. 1983;2(8347):431-433.
  106. Galicia-Poblet G, Cid-Paris E, Lopez-Andres N, et al. A Pediatric Case Report of Ferroportin Disease. *J Pediatr Gastroenterol Nutr*. 2015;63(6):e205-e207.
  107. Mistry PK, Lopez G, Schiffmann R, Barton NW, Weinreb NJ, Sidransky E. Gaucher disease: Progress and ongoing challenges. *Mol Genet Metab*. 2017;120(1-2):8-21.
  108. Beaumont C, Leneuve P, Devaux I, et al. Mutation in the iron responsive element of the L ferritin mRNA in a family with dominant hyperferritinaemia and cataract. *Nat Genet*. 1995;11(4):444-446.
  109. Kannengiesser C, Jouanolle AM, Hetet G, et al. A new missense mutation in the L ferritin coding sequence associated with elevated levels of glycosylated ferritin in serum and absence of iron overload. *Haematologica*. 2009;94(3):335-339.
  110. Miyajima H, Nishimura Y, Mizoguchi K, Sakamoto M, Shimizu T, Honda N. Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration. *Neurology*. 1987;37(5):761-767.
  111. Heilmeyer L, Keller W, Vivell O, Betke K, Woehler F, Keiderling W. [Congenital atransferrinemia]. *Schweiz Med Wochenschr*. 1961;91:1203.
  112. Pietrangelo A, Corradini E, Ferrara F, et al. Magnetic resonance imaging to identify classic and nonclassic forms of ferroportin disease. *Blood Cells Mol Dis*. 2006;37(3):192-196.